Methemoglobin formation by hydroxylamine metabolites of sulfamethoxazole and dapsone: Implications for differences in adverse drug reactions

Journal of Pharmacology and Experimental Therapeutics

Volumn 288, Issue 3, 1999, Pages 951-959

  Reilly, Timothy P ^a   Woster, Patrick M ^a   Svensson, Craig K ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DAPSONE; HYDROXYLAMINE; METHEMOGLOBIN; SULFAMETHOXAZOLE;

AEROBIC METABOLISM; ARTICLE; CELL LYSATE; DETOXIFICATION; DRUG DISPOSITION; DRUG HYPERSENSITIVITY; DRUG POTENCY; ENZYME ACTIVITY; ERYTHROCYTE MEMBRANE; HEMOLYSIS; HUMAN; HUMAN CELL; METHEMOGLOBINEMIA; MONONUCLEAR CELL; PRIORITY JOURNAL; PROPHYLAXIS;

DAPSONE; ERYTHROCYTES; HUMANS; HYDROXYLAMINE; HYDROXYLAMINES; METABOLIC DETOXICATION, DRUG; METHEMOGLOBIN; REACTIVE OXYGEN SPECIES; SULFAMETHOXAZOLE;

EID: 0033028710     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Ahmadi M, Khalaf L, Smith H and Nicholls P (1996) A dapsone-induced blood dyscrasia in the mouse: Evidence for the role of an active metabolite. J Pharm Pharmacol 48:228-232.
2. Beumont MG, Graziani A, Ubel PA and MacGregor RR (1996) Safety of dapsone as pneumocystis carinii pneumonia prophylaxis in human immunodeficiency virus-infected patients with allergy to trimethoprim/sulfamethoxazole. Am J Med 100: 611-616.
3. Carr A, Tindall B, Penny R and Cooper DA (1993) In vitro cytotoxicity as a marker of hypersensitivity to sulphamethoxazole in patients with HIV. Clin Exp Immunol 94:21-25.
4. Coleman MD, Ogg M, Holmes J, Gardiner J and Jacobus D (1996) Studies on the differential sensitivity between diabetic and non-diabetic human erythrocytes to monoacetyl dapsone hydroxylamine-mediated methaemoglobin formation in vitro. Environ Toxicol Pharmacol 1:97-192.
5. Coleman MD (1995) Dapsone toxicity: Some current perspectives. Gen Pharmacol 26:1461-1467.
6. Coleman MD, Breckenridge AM and Park BK (1989) Bioactivation of dapsone to a cytotoxic metabolite by human hepatic microsomal enzymes. Br J Clin Pharmacol 28:389-395.
7. Coleman MD and Jacobus DP (1993) Reduction of dapsone hydroxylamine to dapsone during methaemoglobin formation in human erythrocytes in vitro. Biochem Pharmacol 45:1027-1033.
8. Coleman MD, Scott AK, Breckenridge AM and Park BK (1990) The use of cimetidine as a selective inhibitor of dapsone N-hydroxylation in man. Br J Clin Pharmacol 30:761-767.
9. Coleman MD, Simpson J and Jacobus DP (1994a) Reduction of dapsone hydroxylamine to dapsone during methaemoglobin formation in human erythrocytes in vitro. III: Effect of diabetes. Biochem Pharmacol 48:1341-1347.
10. Coleman MD, Simpson J and Jacobus DP (1994b) Reduction of dapsone hydroxylamine to dapsone during methaemoglobin formation in human erythrocytes in vitro. IV: Implications for the development of agranulocytosis. Biochem Pharmacol 48:1349-1354.
11. Cribb AE, Lee BL, Trepanier LA and Spielberg SP (1996a) Adverse reactions to sulphonamide and sulphonamide-trimethoprim antimicrobials: clinical syndromes and pathogenesis. Adverse Drug React Toxicol Rev 15:9-50.
12. Cribb AE, Miller M, Leeder JS, Hill J and Spielberg SP (1991) Reactions of the nitroso and hydroxylamine metabolites of sulfamethoxazole with reduced glutathione. Implications for idiosyncratic toxicity. Drug Metab Dispos 19:900-906.
13. Cribb AE, Nuss CE, Alberts DW, Lamphere DB, Grant DM, Grossman SJ and Spielberg SP (1996b) Covalent binding of sulfamethoxazole reactive metabolites to human and rat liver subcellular fractions assessed by immunochemical detection. Chem Res Toxicol 9:500-507.
14. Cribb AE and Spielberg SP (1992) Sulfamethoxazole is metabolized to the hydroxylamine in humans. Clin Pharmacol Ther 51:522-526.
15. Fairbanks VF and Klee GG (1987) Biochemical aspects of hematology, Fundamentals of Clinical Chemistry (Tietze NW ed) pp 789-824, WB Saunders, Philadelphia.
16. Fariss M and Reed D (1987) High-performance liquid chromatography of thiols and disulfides: Dinitrophenol derivatives. Methods Enzymol 143:101-109.
17. Gaetani GF, Ferraris AM, Rolfo M, Mangerini R, Arena S and Kirkman HN (1996) Predominant role of catalase in the disposal of hydrogen peroxide within human erythrocytes. Blood 87:1595-1599.
18. Gallant J, Moore R and Chaisson R (1994) Prophylaxis for opportunistic infections in patients with HIV infection. Ann Intern Med 120:932-934.
19. Glader B and Conrad M (1973) Hemolysis by diphenylsulfones: Comparative effects of DDS and hydroxylamine DDS. J Lab Clin Med 81:267-272.
20. Glock GE and McLean P (1953) Further studies on the properties and assay of glucose 6-phosphate dehydrogenase and 6-phosphogluconate dehydrogenase of rat liver. Biochem J 55:400-408.
21. Grossman S, Budinsky R and Jollow D (1995) Dapsone-induced hemolytic anemia: Role of glucose-6-phosphate dehydrogenase in the hemolytic response of rat erythrocytes to N-hydroxydapsone. J Pharmacol Exp Ther 273:870-877.
22. Grossman SJ and Jollow DJ (1988) Role of dapsone hydroxylamine in dapsone-induced hemolytic anemia. J Pharmacol Exp Ther 244:118-125.
23. Grossman SJ, Simson J and Jollow DJ (1992) Dapsone-induced hemolytic anemia: Effect of N-hydroxy dapsone on the sulfhydryl status and membrane proteins of rat erythrocytes. Toxicol Appl Pharmacol 117:208-217.
24. Hjelm M and Deverdier C-H (1965) Biological effects of aromatic amines. I. Methaemoglobinemia, hemolysis and Heinz-body formation induced by 4,4′-diaminodiphenylsulfone. Biochem Pharmacol 14:1119-1128.
25. Jollow DJ, Bradshaw TP and McMillan DC (1995) Dapsone-induced hemolytic anemia. Drug Metab Rev 27:107-124.
26. Kiese M (1966) The biochemical production of ferrihemoglobin-forming derivatives from aromatic amines, and mechanisms of ferrihemoglobin formation. Pharmacol Rev 18:1091-1161.
27. Kirkman HN and Gaetani GF (1984) Catalase: A tetrameric enzyme with four tightly bound molecules of NADPH. Proc Natl Acad Sci USA 81:4343-4347.
28. Kramer PA, Glader BE and Li T-K (1972) Mechanism of methemoglobin formation by diphenylsulfone: Effect of 4-amino-4′-hydroxyaminodiphenylsulfone and other p-substituted derivatives. Biochem Pharmacol 21:1265-1274.
29. Leanderson P, Zackrisson A-L, Tagesson C, Boswell G, Kerr J and Bassett, D (1994) EDU decreases polymorphonuclear leukocyte production of reactive oxygen intermediates. Res Commun Chem Pathol Pharmacol 84:133-141.
30. Lee B, Medina I, Benowitz N, Jacob P, Wofsy C and Mills J (1989) Dapsone, trimethoprim and sulfamethoxazole plasma levels during treatment of pneumocystis pneumonia in patients with the acquired immunodeficiency syndrome (AIDS): Evidence of drug interactions. Ann Intern Med 110:606-611.
31. Margoliash E and Novogrodsky A (1958) A study of the inhibition of catalase by 3-amino-1:2:4-triazole. Biochem J 68:468-475.
32. Margoliash E, Novogrodsky A and Schejter A (1960) Irreversible reaction of 3-amino-1:2:4-triazole and related inhibitors with the protein catalase. Biochem J 74:339-348.
33. Medina I, Mills J, Leoung G, Hopewell P, Lee B, Modin G, Benowitz N and Wofsy C (1990) Oral therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome: A controlled trial of trimethoprim-sulfamethoxazole vs. trimethoprim-dapsone. N Engl J Med 323:776-782.
34. Pertel P and Hirschtick R (1994) Adverse reactions to dapsone in persons infected with immunodeficiency virus. Clin Infect Dis 18:630-632.
35. Rasbridge M and Scott G (1973) The haemolytic action of dapsone: Changes in red-cell membrane. Br J Haematol 24:183-193.
36. Reilly TP, Frank H, Bellevue I, Woster PM and Svensson CK (1998) Comparison of the in vitro cytotoxicity of hydroxylamine metabolites of sulfamethoxazole and dapsone. Biochem Pharmacol 55:803-810.
37. Rieder MJ, Uetrecht J, Shear NH, Cannon M, Miller M and Spielberg SP (1989) Diagnosis of sulfonamide hypersensitivity reactions by in-vitro "rechallengewith hydroxylamine metabolites. Ann Intern Med 110:286-289.
38. Rieder MJ, Uetrecht J, Shear NH and Spielberg SP (1988) Synthesis and in vitro toxicity of hydroxylamine metabolites of sulfonamides. J Pharmacol Exp Ther 244:724-728.
39. Scott G and Rasbridge M (1973) The in vitro action of dapsone and its derivatives on normal and G6PD-deficient red cells. Br J Haematol 24:307-317.
40. Scott MD, Lubin BH, Zuo L and Kuypers FA (1991a) Erythrocyte defense against hydrogen peroxide. Preeminent importance of catalase. J Lab Clin Med 118:7-16.
41. Scott MD, Zuo L, Lubin BH and Chiu DT (1991b) NADPH, not glutathione, status modulates oxidant sensitivity in normal and glucose-6-phosphate dehydrogenase-deficient erythrocytes. Blood 77:2059-2064.
42. Stevens T, GA Boswell J, Adler R, Ackerman N and Kerr J (1988) Induction of antioxidant enzyme activities by phenylurea derivative, EDU. Toxicol Appl Pharmacol 96:33-42.
43. Tingle MD, Mahmud R, Maggs JL, Pirmohamed M and Park BK (1997) Comparison of the metabolism and toxicity of dapsone in rat, mouse and man. J Pharmacol Exp Ther 283:817-823.
44. Tingle MD and Park BK (1993) The use of a three compartment in vitro model to investigate the role of hepatic drug metabolism in drug-induced blood dyscrasias. Br J Clin Pharnmcol 36:31-38.
45. Torres R, Barr M, Thorn M, Gregory G, Kiely S, Chanin E, Carlo C, Martin M and Thorton J (1993) Randomized trial of dapsone and aerosolized pentamidine for the prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis. Am J Med 95:573-583.
46. Vage C, Saab N, Woster PM and Svensson CK (1994) Dapsone-induced hematologic toxicity: Comparison of the methemoglobin-forming ability of hydroxylamine metabolites of dapsone in rat and human blood. Toxicol Appl Pharmacol 129:309-316.
47. van der Ven A, Mantel M, Vree T, Koopmans P and van der Meer J (1994) Formation and elimination of sulfamethoxazole hydroxylamine after oral administration of sulfamethoxazole. Br J Clin Phamacol 38:147-150.